Elanco Q2 Earnings Crush Estimates, Raises Full-Year Outlook on Pet Health Boom
ELAN sits 92% above its 52-week low of $13.76.
Summary
Elanco delivered a standout Q2, with adjusted EPS of $0.34 beating consensus by 26% and revenue of $1.368B topping estimates by $55M. Pet Health revenue surged 12% to $718M, fueled by strong uptake of Zenrelia and Credelio Quattro—Zenrelia alone reached 18,000 vet clinics with June its biggest month yet. Management raised full-year guidance: revenue now $5.09B-$5.14B (up from $5.01B-$5.085B) and adjusted EPS to $1.10-$1.16 (from $1.03-$1.09), both above consensus. The company also provided Q3 guidance roughly in line with expectations. Margin expansion is accelerating, with the Elanco Ascend program on track for $200M-$250M in EBITDA savings by 2030, and leverage improved to 3.1x, nearing the sub-3x target that could unlock capital flexibility. This follows the earlier revenue guidance headline this morning, adding full earnings details and segment color that confirm broad-based momentum.
At the time of this announcement, ELAN was trading at $26.38 on NYSE in the Life Sciences sector, with a market capitalization of approximately $13.2B. The 52-week trading range was $13.76 to $27.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.